[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581049":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Xiyuan Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g\u002F tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks",[13],"Drug: Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) +Placebo capsule, 0.33g\u002F tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks",[19],"Drug: placebo capsule",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)","Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g\u002F tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"placebo capsule","Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g\u002F tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Dazhuo Shi, professor","CONTACT","010-62835303","shidazhuo@126.com",[38],{"facility":39,"status":26,"city":40,"state":26,"zip":26,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Xiyuan Hospital, China Academy of Chinese Medical Sciences","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":52,"phoneExt":26,"email":36},"Dazhuo Shi","17611487217",{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100581049","phase-3-clinical-study-on-the-intervention-of-xuesaitong-soft-capsules-in-post-intervention-patients-with-acute-coronary-syndrome-and-clinical-research-protocol-100581049",false,"NCT06845254","Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol","Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, or unstable angina according to Western medical standards. Inclusion Criteria.\n2. Within 4 weeks post-PCI.\n3. Aged between 18 and 80 years, both male and female.\n4. Voluntarily participating in the clinical trial, having signed the informed consent form.\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension after medication (systolic BP \\>180mmHg or diastolic BP \\> 110mmHg).\n2. Increased bleeding risk: history of hemorrhagic stroke; intracranial aneurysm; major trauma or surgery within the past month (including Exclusion Criteria bypass surgery); active bleeding disorders.\n3. History of gastrointestinal ulcers or significant gastrointestinal bleeding.\n4. Severe organic heart disease, such as LVEF \\\u003C 35% or NYHA\u002FKillip heart function grade IV.\n5. History of malignant arrhythmias within the past year (arrhythmias affecting hemodynamics requiring medication or electrical cardioversion, or requiring CPR), congenital heart disease, or malignant tumors.\n6. Severe liver or kidney dysfunction: ALT or AST ≥ 3×ULN, TBIL≥ 2×ULN, or creatinine clearance \\\u003C 30ml\u002Fmin.\n7. Pregnant or lactating women.\n8. Recent blood donation or significant blood loss within the past 3 months (≥400ml).\n9. History of alcohol abuse (≥28 standard units\u002Fweek for males, ≥21 standard units\u002Fweek for females) or frequent alcohol consumption in the past 6 months (≥14 standard units\u002Fweek).\n10. History of drug abuse or dependence within the past year. Participation in other clinical trials and taking trial drugs within the past 3 months.\n11. Allergy or intolerance to aspirin or P2Y12 receptor inhibitors.\n12. Allergy to any components of the trial drug.\n13. Other conditions deemed inappropriate for participation by the nvestigator","ALL","18 Years","80 Years",{"count":66,"type":67},400,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.",[73],"Acute Coronary Syndrome",[75,76,77],"Acute coronary syndrome","traditional Chinese medicine","Total saponins of Panax notoginseng","NOT_YET_RECRUITING","2025-02-23",{"date":81,"type":82},"2025-02-25","ACTUAL",{"date":84,"type":67},"2025-03-01",{"date":86,"type":67},"2026-12-01",{"name":5,"class":6},1]